pharma · Breast Cancer · NSCLC (Advanced Non-small Cell Lung Cancer) · ALXO
ALX ONCOLOGY HOLDINGS
ALX ONCOLOGY HOLDINGS INC
ALX ONCOLOGY HOLDINGS is a pharma organization headquartered in San Antonio, USA. It trades on NYSE under ticker ALXO. Primary therapeutic focus areas include Breast Cancer, NSCLC (Advanced Non-small Cell Lung Cancer), A
Company details
- Status
- Public
- HQ
- 4545 Horizon Hill Blvd, San Antonio, Texas 78229-2263, US
- Founded
- 2015
- Employees
- 2
- Programs
- 13
- Drugs
- 16
- Patents
- 0
Quick answer
ALX ONCOLOGY HOLDINGS is a pharma organization headquartered in San Antonio, USA. It trades on NYSE under ticker ALXO. Primary therapeutic focus areas include Breast Cancer, NSCLC (Advanced Non-small Cell Lung Cancer), Acute Myeloid Leukemia, Breast Cancer, Metastatic, Gastric Cancer. NovaPharmaNews links 13 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (7), phase 1 (5), phase 3 (1).
Company snapshot
ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, evorpacept (also known as ALX148), is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain w
- 13 active pipeline program(s) linked via ClinicalTrials.gov.
- 13 trial update(s) in the last 12 months.
Public regulatory, clinical, patent, and corporate records for ALX ONCOLOGY HOLDINGS. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- approval
ALX Oncology to Present at 2026 Jefferies Global Healthcare Conference, Highlighting Oncology Pipeline
Recent coverage
Top assets
Lead pipeline drugs
- approved
- approved
- approved
- approved
Active clinical programs
- Phase 3
- Phase 2
- Phase 2
- Phase 2
Momentum
Proprietary activity score for ALX ONCOLOGY HOLDINGS.
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for ALX ONCOLOGY HOLDINGS.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is ALX ONCOLOGY HOLDINGS?
-
Is ALX ONCOLOGY HOLDINGS publicly traded?
-
What drugs does ALX ONCOLOGY HOLDINGS develop or market?
-
What are the latest developments for ALX ONCOLOGY HOLDINGS?
-
What therapeutic areas does ALX ONCOLOGY HOLDINGS focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.